Literature DB >> 34070835

Associations between High-Density Lipoprotein Functionality and Major Adverse Cardiovascular Events in Patients Who Have Undergone Coronary Computed Tomography Angiography.

Hiroko Inoue1, Yuhei Shiga2, Kenji Norimatsu1,2, Kohei Tashiro2, Makito Futami1,2, Yasunori Suematsu2, Makoto Sugihara2, Hiroaki Nishikawa1, Yousuke Katsuda1, Shin-Ichiro Miura1,2.   

Abstract

The present study aimed to investigate the associations between high-density lipoprotein (HDL) functionality and major adverse cardiovascular events (MACE) in patients who have undergone coronary computed tomography angiography (CCTA). We performed a prospective cohort study and enrolled 151 patients who underwent CCTA and had a follow-up of up to 5 years. We measured cholesterol efflux capacity (CEC), caspase-3/7 activity and monocyte chemoattractant protein-1 (MCP-1) secretion as bioassays of HDL functionality. The patients were divided into MACE(-) (n = 138) and MACE(+) (n = 13) groups. While there was no significant difference in %CEC, caspase-3/7 activity or MCP-1 secretion between the MACE(-) and MACE(+) groups, total CEC and HDL cholesterol (HDL-C) in the MACE(+) group were significantly lower than those in the MACE(-) group. Total CEC was correlated with HDL-C. A receiver-operating characteristic curve analysis showed that there was no significant difference between the areas under the curves for total CEC and HDL-C. In conclusion, total CEC in addition to HDL-C, but not %CEC, was associated with the presence of MACE. On the other hand, HDL functionality with regard to anti-inflammatory and anti-apoptosis effects was not associated with MACE.

Entities:  

Keywords:  cholesterol efflux capacity; high-density lipoprotein; major adverse cardiovascular events

Year:  2021        PMID: 34070835     DOI: 10.3390/jcm10112431

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  29 in total

Review 1.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.

Authors:  James H O'Keefe; Loren Cordain; William H Harris; Richard M Moe; Robert Vogel
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

2.  Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.

Authors:  Dick C Chan; Anh Hoang; P Hugh R Barrett; Annett T Y Wong; Paul J Nestel; Dmitri Sviridov; Gerald F Watts
Journal:  J Clin Endocrinol Metab       Date:  2012-06-28       Impact factor: 5.958

3.  HDL cholesterol efflux capacity and incident cardiovascular events.

Authors:  Anand Rohatgi; Amit Khera; Jarett D Berry; Edward G Givens; Colby R Ayers; Kyle E Wedin; Ian J Neeland; Ivan S Yuhanna; Daniel R Rader; James A de Lemos; Philip W Shaul
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

Review 4.  HDL dysfunction in diabetes: causes and possible treatments.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

5.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

6.  Effect of High-Density Lipoprotein Cholesterol Levels on Overall Survival and Major Adverse Cardiovascular and Cerebrovascular Events.

Authors:  Manpreet Kaur; Keerat Rai Ahuja; Shameer Khubber; Leon Zhou; Beni Rai Verma; Chandramohan Meenakshisundaram; Mohamed M Gad; Anas Saad; Kamalpreet Dhaliwal; Toshiaki Isogai; Jeevanatham Rajeswaran; Andrew Toth; Johnny Chahine; Leslie Cho; Rishi Puri; Samir Kapadia
Journal:  Am J Cardiol       Date:  2021-01-31       Impact factor: 2.778

7.  Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease.

Authors:  Christiane L Haase; Anne Tybjærg-Hansen; Peer Grande; Ruth Frikke-Schmidt
Journal:  J Clin Endocrinol Metab       Date:  2010-09-08       Impact factor: 5.958

Review 8.  Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease.

Authors:  Yan Dong; Hengwen Chen; Jialiang Gao; Yongmei Liu; Jun Li; Jie Wang
Journal:  J Mol Cell Cardiol       Date:  2019-09-07       Impact factor: 5.000

9.  Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.

Authors:  Manabu Ogita; Katsumi Miyauchi; Tadashi Miyazaki; Ryo Naito; Hirokazu Konishi; Shuta Tsuboi; Tomotaka Dohi; Takatoshi Kasai; Takayuki Yokoyama; Shinya Okazaki; Takeshi Kurata; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2013-03-21       Impact factor: 2.037

10.  Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment.

Authors:  Yi-Heng Li; Wei-Kung Tseng; Wei-Hsian Yin; Fang-Ju Lin; Yen-Wen Wu; I-Chang Hsieh; Tsung-Hsien Lin; Wayne Huey-Herng Sheu; Hung-I Yeh; Jaw-Wen Chen; Chau-Chung Wu
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.